FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136166831> ?p ?o ?g. }

• W3136166831 endingPage "384" @default.
• W3136166831 startingPage "369" @default.
• W3136166831 abstract "Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient self-administration and hence long-term chronic treatment that could enable messenger RNA (mRNA) to be used as a novel modality for protein replacement or regenerative therapies. In this study, we show that subcutaneous administration of mRNA formulated within LNPs can result in measurable plasma exposure of a secreted protein. However, subcutaneous administration of mRNA formulated within LNPs was observed to be associated with dose-limiting inflammatory responses. To overcome this limitation, we investigated the concept of incorporating aliphatic ester prodrugs of anti-inflammatory steroids within LNPs, i.e., functionalized LNPs to suppress the inflammatory response. We show that the effectiveness of this approach depends on the alkyl chain length of the ester prodrug, which determines its retention at the site of administration. An unexpected additional benefit to this approach is the prolongation observed in the duration of protein expression. Our results demonstrate that subcutaneous administration of mRNA formulated in functionalized LNPs is a viable approach to achieving systemic levels of therapeutic proteins, which has the added benefits of being amenable to self-administration when chronic treatment is required. Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient self-administration and hence long-term chronic treatment that could enable messenger RNA (mRNA) to be used as a novel modality for protein replacement or regenerative therapies. In this study, we show that subcutaneous administration of mRNA formulated within LNPs can result in measurable plasma exposure of a secreted protein. However, subcutaneous administration of mRNA formulated within LNPs was observed to be associated with dose-limiting inflammatory responses. To overcome this limitation, we investigated the concept of incorporating aliphatic ester prodrugs of anti-inflammatory steroids within LNPs, i.e., functionalized LNPs to suppress the inflammatory response. We show that the effectiveness of this approach depends on the alkyl chain length of the ester prodrug, which determines its retention at the site of administration. An unexpected additional benefit to this approach is the prolongation observed in the duration of protein expression. Our results demonstrate that subcutaneous administration of mRNA formulated in functionalized LNPs is a viable approach to achieving systemic levels of therapeutic proteins, which has the added benefits of being amenable to self-administration when chronic treatment is required." @default.
• W3136166831 created "2021-03-29" @default.
• W3136166831 creator A5003556588 @default.
• W3136166831 creator A5005833302 @default.
• W3136166831 creator A5012168352 @default.
• W3136166831 creator A5013273787 @default.
• W3136166831 creator A5018809376 @default.
• W3136166831 creator A5021924132 @default.
• W3136166831 creator A5021978873 @default.
• W3136166831 creator A5025349783 @default.
• W3136166831 creator A5030920123 @default.
• W3136166831 creator A5034689784 @default.
• W3136166831 creator A5036210337 @default.
• W3136166831 creator A5044130381 @default.
• W3136166831 creator A5044933218 @default.
• W3136166831 creator A5048811821 @default.
• W3136166831 creator A5048820091 @default.
• W3136166831 creator A5049706887 @default.
• W3136166831 creator A5058949331 @default.
• W3136166831 creator A5067435103 @default.
• W3136166831 creator A5070282117 @default.
• W3136166831 creator A5070375985 @default.
• W3136166831 creator A5073186051 @default.
• W3136166831 creator A5075611143 @default.
• W3136166831 creator A5085844935 @default.
• W3136166831 creator A5086616447 @default.
• W3136166831 date "2021-06-01" @default.
• W3136166831 modified "2023-10-16" @default.
• W3136166831 title "Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein" @default.
• W3136166831 cites W1420726270 @default.
• W3136166831 cites W1511669342 @default.
• W3136166831 cites W1745264954 @default.
• W3136166831 cites W1808439685 @default.
• W3136166831 cites W1963706689 @default.
• W3136166831 cites W1977160822 @default.
• W3136166831 cites W1995770815 @default.
• W3136166831 cites W1996147982 @default.
• W3136166831 cites W2000071382 @default.
• W3136166831 cites W2002830509 @default.
• W3136166831 cites W2006120701 @default.
• W3136166831 cites W2011850720 @default.
• W3136166831 cites W2037313242 @default.
• W3136166831 cites W2045875672 @default.
• W3136166831 cites W2059355578 @default.
• W3136166831 cites W2092236844 @default.
• W3136166831 cites W2098419906 @default.
• W3136166831 cites W2106885643 @default.
• W3136166831 cites W2122364696 @default.
• W3136166831 cites W2133171074 @default.
• W3136166831 cites W2143743183 @default.
• W3136166831 cites W2156788486 @default.
• W3136166831 cites W2167833923 @default.
• W3136166831 cites W2171303876 @default.
• W3136166831 cites W2249755146 @default.
• W3136166831 cites W2339678112 @default.
• W3136166831 cites W2340906209 @default.
• W3136166831 cites W2474278012 @default.
• W3136166831 cites W2587850379 @default.
• W3136166831 cites W2587871737 @default.
• W3136166831 cites W2607297673 @default.
• W3136166831 cites W2630192492 @default.
• W3136166831 cites W2738515079 @default.
• W3136166831 cites W2745973480 @default.
• W3136166831 cites W2754401101 @default.
• W3136166831 cites W2774359469 @default.
• W3136166831 cites W2777634859 @default.
• W3136166831 cites W2791837202 @default.
• W3136166831 cites W2791854174 @default.
• W3136166831 cites W2793806408 @default.
• W3136166831 cites W2794867971 @default.
• W3136166831 cites W2797607167 @default.
• W3136166831 cites W2806127886 @default.
• W3136166831 cites W2810909862 @default.
• W3136166831 cites W2883914951 @default.
• W3136166831 cites W2885263529 @default.
• W3136166831 cites W2901779366 @default.
• W3136166831 cites W2908312876 @default.
• W3136166831 cites W2914060533 @default.
• W3136166831 cites W2914083560 @default.
• W3136166831 cites W3007447370 @default.
• W3136166831 cites W3109389550 @default.
• W3136166831 doi "https://doi.org/10.1016/j.omtn.2021.03.008" @default.
• W3136166831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8039535" @default.
• W3136166831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33868782" @default.
• W3136166831 hasPublicationYear "2021" @default.
• W3136166831 type Work @default.
• W3136166831 sameAs 3136166831 @default.
• W3136166831 citedByCount "37" @default.
• W3136166831 countsByYear W31361668312021 @default.
• W3136166831 countsByYear W31361668312022 @default.
• W3136166831 countsByYear W31361668312023 @default.
• W3136166831 crossrefType "journal-article" @default.
• W3136166831 hasAuthorship W3136166831A5003556588 @default.
• W3136166831 hasAuthorship W3136166831A5005833302 @default.
• W3136166831 hasAuthorship W3136166831A5012168352 @default.
• W3136166831 hasAuthorship W3136166831A5013273787 @default.
• W3136166831 hasAuthorship W3136166831A5018809376 @default.
• W3136166831 hasAuthorship W3136166831A5021924132 @default.

• next